Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocolMatthew R. Sydes, Nicholas D. James, Melissa Spears et al.|Annals of Oncology|2018Cited by 252
Comprehensive Geriatric Assessment in Men Aged 70 Years or Older with Localised Prostate Cancer Undergoing Radical RadiotherapyG.E.C. Osborne, Alistair Ring, Sharon A. Appleyard et al.|Clinical Oncology|2017Cited by 27
Comprehensive geriatric assessment (CGA) in men age 70 or over with localized prostate cancer.G.E.C. Osborne, Alistair Ring, Angus Robinson et al.|Journal of Clinical Oncology|2014Cited by 0
Patient Reported Toxicity, Quality of Life and Biochemical Control Following HDR Brachytherapy: Outcomes from the First 2 Years of a New Service at the Sussex Cancer CentreSharon A. Appleyard, Ashok Nikapota, F. Cowtan et al.|Clinical Oncology|2019Cited by 0
Outcomes following HDR Brachytherapy Boost for High Risk Localised Prostate Cancer: Data from a UK CentreC. Lorimer, Ashok Nikapota, B. Ravi et al.|Clinical Oncology|2023Cited by 0